Labcorp Holdings Earnings Preview: Analysts Expect Single-Digit Growth

Got story updates? Submit your updates here. ›

Labcorp Holdings Inc., a leading provider of clinical laboratory services, is expected to announce its fiscal first-quarter 2026 earnings before the market opens on Thursday, April 30. Analysts anticipate the company to report a profit of $4.10 per share, up 6.8% from the year-ago quarter, as Labcorp has consistently surpassed Wall Street's EPS estimates in its last four quarterly reports.

Why it matters

As a global leader in innovative laboratory services, Labcorp's earnings report will provide insights into the healthcare industry's performance and trends, particularly in areas like allergy testing, genetics, cancer screening, and COVID-19 clinical trials. The company's results could also signal broader economic conditions and consumer spending patterns.

The details

Labcorp Holdings, headquartered in Burlington, North Carolina, provides a wide range of clinical laboratory tests and services. The $21.5 billion company specializes in areas such as allergies, genetics, colorectal cancer, diabetes, chronic kidney disease, and pregnancy, as well as COVID-19 clinical trials. For the full fiscal year 2026, analysts expect Labcorp to report earnings per share of $17.66, up 7.4% from the previous year.

• Labcorp Holdings will announce its Q1 2026 earnings on Thursday, April 30, 2026, before the market opens.
• In the company's most recent Q4 2025 report, its adjusted EPS of $4.07 beat Wall Street expectations of $3.95.

What’s next

Investors will be closely watching Labcorp's Q1 2026 earnings report for signs of continued growth and any updates on the company's strategic initiatives, particularly in the areas of COVID-19 testing and clinical trials.